Victrelis combo therapy anaemia: new study shows reducing ribavirin just as effective as adding EPO
This article was originally published in Scrip
Executive Summary
Merck has announced results of a Phase III study demonstrating no difference in the rates of viral clearance between two anaemia management strategies (reducing the dose of ribavirin or adding EPO) for patients with chronic C virus genotype 1 infection treated with Victrelis (boceprevir) in combination with peg-interferon alfa-2b and ribavirin.